Management of trastuzumab-related cardiac dysfunction

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 130-139

  Carver, Joseph R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Cardiac dysfunction; Cardiac output; ERB2; Heart failure; Signal transduction; Trastuzumab

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL ASSESSMENT; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LABORATORY TEST; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT MONITORING; RETREATMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; HEART LEFT VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEART FAILURE; HUMANS; RISK ASSESSMENT; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77955858664     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.07.001     Document Type: Article

References (55)

1. Park J.W., Neve R.M., Szollosi J., et al. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008, 8:392-401.
2. Sjogren S., Inganas M., Lindgren A., et al. Progressive and predictive value of c-erB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998, 16:462-469.
3. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancerL correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
4. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5:63-69.
5. Press M.F., Pike M.C., Chazin G., et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993, 53:4960-4970.
6. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15:2894-2904.
7. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
8. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
9. Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007, 25:6s. (abstr 512).
10. Slamon D.J., Eiermann W., Robert N.J., et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94(Suppl 1):S5. (abstr 1).
11. Slamon D., Eiermann W., Robert N., et al. BCIRG 006: phase III Trial comparing AC→T with AC→TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis 2009, (abstr 62).
12. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
13. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
14. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
15. Seidman A.D., Fornier M.N., Esteva F.J. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001, 19:2587-2595.
16. Seidman A.D., Berry D., Cirrincione C., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008, 26:1642-1649.
17. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006, 24:2786-2792.
18. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005, 23:4265-4274.
19. Pegram M., Forbes J.F., Pienkowski T., et al. First overall survival analysis of a multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as, first line chemotherapy for patients with metastatic breast cancer containing the HER2/neu alteration. J Clin Oncol 2007, 25:34s. (abstr LBA1008).
20. Burstein H.J., Harris L.N., Marcom P.K., et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003, 21:2889-2895.
21. O'Shaughnessy J., Vukelja S.J., Marsland T., et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 2002, 3(Suppl 1):17-20.
22. Wardley A., Antón-Torres A., Pivot X., et al. Evaluation of trastuzumab (Herceptin), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):S33. (abstr 309).
23. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
24. Rastogi P., Jeong J., Geyer C.E., et al. Five year update of cardiac dysfunction on NSABP B-31. A randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab. J Clin Oncol 2007, 25:6s. (abstr LBA513).
25. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
26. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac events in the Herceptin adjuvant trial. J Clin Oncol 2007, 25:3859-3865.
27. Joensuu H., Bono P., Kataja V., et al. Fluorouracil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009, 27:5685-5692.
28. Lee K.F., Simon H., Chen H., et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378:394-398.
29. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
30. Negro A., Brar B.K., Lee K. Essential roles of HER2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004, 59:1-12.
31. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
32. Chien K.R. Herceptin and the heart. A molecular modifier of cardiac failure. N Engl J Med 2006, 354:789-790.
33. Zhao Y.Y., Sawyer D.R., Baliga R.R., et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998, 273:10261-10269.
34. Doroshow J.H., Locker G.Y., Myers C.E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980, 65:128-135.
35. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23:2900-2902.
36. Ewer M.S., O'Shaughnessy J.A. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer 2007, 7:600-607.
37. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
38. Perez E.A., Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004, 22:322-329.
39. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA guidelines for diagnosis and treatment of heart failure in adults. J Am Col Card 2009, 53:1343-1382.
40. Carver J.R., Shapiro C.L., Ng A., et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007, 25:3991-4008.
41. Fox K.F. The evaluation of left ventricular function for patients being considered for or receiving Trastuzumab (Herceptin) therapy. Brit J Cancer 2006, 95:1454.
42. Sparano J.A., Brown D.L., Wolff A.C. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002, 25:301-3011.
43. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109:2749-2754.
44. Lenihan D., Massey M.R., Baysinger K.B., et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail 2007, 13(6 Suppl 2):S151. (abstr 265).
45. Kutteh L.A., Hobday T., Jaffe A., et al. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2-positive breast cancer. J Clin Oncol 2007, 25(Suppl 18S):579. (2007 ASCO annual meeting proceedings).
46. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Breast cancer V.1.2009. Available at:, Accessed March 31, 2009. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
47. Shenoy M., Chapman C.B., Nawaz M.Z., et al. Diagnosis and management of stage A heart failure. Congest Heart Fail 2006, 12146-12152.
48. Ewer M.S., Perez E.A., Baselga J., et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer. Breast 2007, 16(Suppl 1):S63.
49. Management of asymptomatic patients with reduced left ventricular ejection fraction. J Card Fail 2006, 12:e26-e28. Heart Failure Society of America.
50. Keefe D.L. Trastuzumab-associated cardiotoxicity. Cancer 2002, 95:1592-1600.
51. Lenihan D., Tong A., Divakaran V., et al. Herceptin (T)-associated cardiomyopathy: sequential stress and response to ACE-inhibitors and carvedilol therapy. J Card Fail 2003, 9(5 Suppl 1):S102. (abst 383).
52. Lenihan D., Tong A., Woods M., et al. Withdrawal of beta blockers and ACE inhibitors in chemotherapy-induced heart failure leads to severe adverse cardiovascular events. J Card Fail 2003, 9(5 Suppl 1):S77. (abstr 281).
53. van der Harst P., Voors A.A., van Gilst W.H., et al. Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006, 71:443-454.
54. Haendeler J., Hoffmann J., Zeiher A.M., et al. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004, 110:856-861.
55. Pocobelli G., Newcomb P.A., Trentham-Dietz A., et al. Statin use and risk of breast cancer. Cancer 2008, 112:27-33.